Radiopharm Theranostics


Radiopharm Theranostics is dedicated to developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, addressing high unmet medical needs. The company is engaged in clinical trials, strategic partnerships, and advancing cancer research with a focus on precision oncology.

Industries

biotechnology
consulting
pharmaceutical
therapeutics

Nr. of Employees

small (1-50)

Radiopharm Theranostics


Products

B7H3-targeted therapeutic — Phase I clinical program

An early-phase clinical program evaluating a B7H3-directed radiotherapeutic in patients with non-small cell lung cancer to assess safety and enable dose selection.


Services

Clinical development and trial execution (in-house)

Conduct of early-phase oncology clinical studies including trial initiation, site activation and study operations for radiopharmaceutical candidates.

Radiopharmaceutical R&D and pipeline advancement

Preclinical and translational development services for diagnostic and therapeutic radioconjugates through candidate selection and clinical transition.

Radioisotope procurement and supply arrangements

Negotiation and establishment of supply agreements for clinical-grade radioisotopes to support manufacturing and clinical supply of radiopharmaceuticals.

Expertise Areas

  • Radiopharmaceutical development
  • Targeted radionuclide therapy
  • Early-phase (Phase I) oncology clinical trials
  • Radioisotope procurement and supply-chain management
  • Show More (3)

Key Technologies

  • Radioconjugates (therapeutic and diagnostic)
  • Lutetium-177 radiotherapy
  • Targeted radionuclide therapy (B7H3-directed)
  • Clinical-grade radioisotope supply
  • Show More (1)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.